News for Regeneron Pharmaceuticals Stock (REGN)

Dupixent® (dupilumab) Approved in the U.S. as First and Only Treatment for Adolescents with Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)

GlobeNewsWire • Friday

Sanofi, Regeneron's Dupixent Meets Late-Stage Urticaria Study Goals

Zacks Investment Research • Wednesday

EYLEA HD® (aflibercept) Injection 8 mg Data at EURETINA Reinforce Long-term Durability, Sustained Fluid Control and Safety Profile

GlobeNewsWire • Wednesday

Prediction: These 2 Companies Will Split Their Stocks by 2027

The Motley Fool • Wednesday

Press Release: Dupixent phase 3 study confirms significant improvements in itch and hives for patients with CSU

GlobeNewsWire • Wednesday

Dupixent® (dupilumab) Phase 3 Trial Confirms Significant Improvements in Itch and Hives for Patients with Chronic Spontaneous Urticaria (CSU)

GlobeNewsWire • Wednesday

Press Release: Dupixent is the first and only biologic to achieve significant improvements in disease remission and symptoms in bullous pemphigoid positive pivotal study

GlobeNewsWire • Wednesday

Dupixent® (dupilumab) Is the First and Only Biologic to Achieve Significant Improvements in Disease Remission and Symptoms in Bullous Pemphigoid (BP) Positive Pivotal Trial

GlobeNewsWire • Wednesday

2 Biotech Stocks To Watch In September 2024

Stockmarketcom • Wednesday

Libtayo® (cemiplimab) Demonstrates Durable Survival Benefit at Five Years in Advanced Non-small Cell Lung Cancer

GlobeNewsWire • Monday

Regeneron to Highlight Progress Across Its Differentiated Oncology Portfolio and Pipeline at WCLC and ESMO

GlobeNewsWire • Monday

Regeneron Pharmaceuticals, Inc. (REGN) Wells Fargo 2024 Healthcare Conference (Transcript)

Seeking Alpha • 09/05/24

Prediction: These 2 Cathie Wood Stocks Could Crush the Market Through 2030

The Motley Fool • 09/05/24

Regeneron Pharmaceuticals, Inc. (REGN) Morgan Stanley 22nd Annual Global Healthcare Conference (Transcript)

Seeking Alpha • 09/05/24

Sonoma Biotherapeutics Receives $45 Million Milestone Payment from Regeneron under Ongoing Collaboration

Business Wire • 09/04/24

Koneksa Announces Regeneron Joins Data Syndication Program for Parkinson's Digital Biomarkers Study

Business Wire • 09/03/24

Regeneron's Bispecific Antibody Obtains EC Nod for Lymphoma

Zacks Investment Research • 08/27/24

Regeneron Stock: Valuation Now Demands More Growth

Seeking Alpha • 08/26/24

HRMY or REGN: Which Is the Better Value Stock Right Now?

Zacks Investment Research • 08/26/24

Ordspono™ (odronextamab) Approved in the European Union for the Treatment of Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-cell Lymphoma

GlobeNewsWire • 08/26/24

Latest Dupixent® (dupilumab) and Itepekimab Data at ERS Highlight Scientific Innovation and Leadership in Respiratory Diseases

GlobeNewsWire • 08/26/24

Regeneron (REGN) Gets CRL From FDA for Multiple Myeloma Drug

Zacks Investment Research • 08/21/24

US FDA declines to approve Regeneron's blood cancer therapy

Reuters • 08/20/24

Regeneron Provides Update on Biologics License Application for Linvoseltamab

GlobeNewsWire • 08/20/24

2 Biotech Stocks To Watch In August 2024

Stockmarketcom • 08/14/24